Discover The Latest Diagnostic Blood Test For Prostate Cancer: Stockholm 3

A diagnosis of prostate cancer from cells can only be set from a histological analysis of the prostate tissue (biopsy). Stockholm3 provides a risk score from blood samples. This risk score is significantly  better than PSA alone for selecting patients suitable for further urological work-up (i.e. an MRI scan as a next step to decide if a prostate biopsy should be taken).

The Stockholm3 test input information from protein analysis (5 different proteins are measured), from genetic testing (a polygenetic risk score off of SNP testing), and combined with clinical information (age, family history, previous biopsy history, use of 5-ARI medications) to provide a combined score, on the risk of having an aggressive prostate cancer.

The answer to this very much depends on how PSA is used (e.g. cut-off of 3, cut-off of 4, age adjusted values). Stockholm3 works already from PSA values of 1.5, and research uniformly shows that 30-50% of aggressive cancers can be found in the PSA range 1.5-3.0 – and these are cancers that would be missed with regular PSA testing. Very impressive sensitivity and specificity data for Stockholm3 have just recently been accepted for an upcoming publication, which clearly demonstrate the diagnostic benefits of using Stockholm3 as a complement to existing PSA testing.